Phaseline

Companies › Neuron23

Neuron23: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NEU-411
LRRK2 inhibitor
LRRK2Phase 2Parkinson DiseaseDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06680830NEU-411Phase 2Parkinson DiseaseNeurologyDec 2027

Targets

LRRK2 (1)

Companies with the same targets

Syntara Denali Therapeutics Eli Lilly

Companies built like this

Syntara Aptinyx Bial R&D Investments SHINKEI Therapeutics NeuroTherapia

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.